{"result": {"id": "2e0664e2-2b2f-4f63-bd95-c6cd14e6edf4", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>华法林<|>person<|>华法林是一种抗凝药物，其光学异构体混合物中S-华法林活性占75%，主要通过CYP2C9代谢，R-华法林主要通过CYP1A2、CYP3A4、CYP2C19代谢。\")\n##\n(\"entity\"<|>CYP2C9<|>organization<|>CYP2C9是一种代谢酶，主要参与华法林的代谢，其活性被抑制会影响华法林的抗凝活性。\")\n##\n(\"entity\"<|>CYP1A2<|>organization<|>CYP1A2是一种代谢酶，主要参与R-华法林的代谢。\")\n##\n(\"entity\"<|>CYP3A4<|>organization<|>CYP3A4是一种代谢酶，主要参与R-华法林的代谢。\")\n##\n(\"entity\"<|>CYP2C19<|>organization<|>CYP2C19是一种代谢酶，主要参与R-华法林的代谢。\")\n##\n(\"entity\"<|>阿司匹林<|>person<|>阿司匹林是一种常用的抗血小板药物，不经CYP450酶代谢，但与甲氨蝶呤竞争肾脏有机阴离子转运体。\")\n##\n(\"entity\"<|>甲氨蝶呤<|>person<|>甲氨蝶呤是一种药物，与阿司匹林竞争肾脏有机阴离子转运体，可能减慢其排泄，增加毒性。\")\n##\n(\"entity\"<|>布洛芬<|>person<|>布洛芬是一种NSAID药物，与阿司匹林竞争作用靶点环氧合酶，长期合用大剂量会削弱阿司匹林的心血管保护作用。\")\n##\n(\"entity\"<|>氯吡格雷<|>person<|>氯吡格雷是一种前体药物，需经过CYP3A4和CYP2C19代谢活化后才能抑制血小板聚集。\")\n##\n(\"entity\"<|>奥美拉唑<|>person<|>奥美拉唑是一种质子泵抑制剂，能与氯吡格雷竞争CYP2C19和CYP3A4的代谢，影响氯吡格雷的活性。\")\n##\n(\"entity\"<|>艾司奥美拉唑<|>person<|>艾司奥美拉唑是一种质子泵抑制剂，能与氯吡格雷竞争CYP2C19和CYP3A4的代谢，影响氯吡格雷的活性。\")\n##\n(\"entity\"<|>兰索拉唑<|>person<|>兰索拉唑是一种质子泵抑制剂，可选择作为与氯吡格雷合用的替代药物。\")\n##\n(\"entity\"<|>泮托拉唑<|>person<|>泮托拉唑是一种质子泵抑制剂，可选择作为与氯吡格雷合用的替代药物。\")\n##\n(\"entity\"<|>雷贝拉唑<|>person<|>雷贝拉唑是一种质子泵抑制剂，可选择作为与氯吡格雷合用的替代药物。\")\n##\n(\"entity\"<|>瑞格列奈<|>person<|>瑞格列奈是一种药物，其代谢可被氯吡格雷的葡糖酸苷代谢物抑制。\")\n##\n(\"entity\"<|>阿托伐他汀<|>person<|>阿托伐他汀是一种血脂调节药，与环孢素或吉非罗齐合用可能增加肌病风险。\")\n##\n(\"entity\"<|>环孢素<|>person<|>环孢素是一种药物，能抑制CYP3A4、P-gp和OATP1B1，显著提高阿托伐他汀的血药浓度。\")\n##\n(\"entity\"<|>吉非罗齐<|>person<|>吉非罗齐是一种药物，能使阿托伐他汀的AUC增加，增加肌病风险。\")\n##\n(\"relationship\"<|>华法林<|>CYP2C9<|>华法林主要通过CYP2C9代谢，其活性被抑制会影响华法林的抗凝活性。<|>8)\n##\n(\"relationship\"<|>华法林<|>CYP1A2<|>R-华法林主要通过CYP1A2代谢。<|>6)\n##\n(\"relationship\"<|>华法林<|>CYP3A4<|>R-华法林主要通过CYP3A4代谢。<|>6)\n##\n(\"relationship\"<|>华法林<|>CYP2C19<|>R-华法林主要通过CYP2C19代谢。<|>6)\n##\n(\"relationship\"<|>阿司匹林<|>甲氨蝶呤<|>阿司匹林与甲氨蝶呤竞争肾脏有机阴离子转运体，可能减慢甲氨蝶呤的排泄。<|>7)\n##\n(\"relationship\"<|>阿司匹林<|>布洛芬<|>布洛芬与阿司匹林竞争作用靶点环氧合酶，长期合用大剂量会削弱阿司匹林的心血管保护作用。<|>7)\n##\n(\"relationship\"<|>氯吡格雷<|>CYP3A4<|>氯吡格雷需经过CYP3A4代谢活化后才能抑制血小板聚集。<|>8)\n##\n(\"relationship\"<|>氯吡格雷<|>CYP2C19<|>氯吡格雷需经过CYP2C19代谢活化后才能抑制血小板聚集。<|>8)\n##\n(\"relationship\"<|>氯吡格雷<|>奥美拉唑<|>奥美拉唑能与氯吡格雷竞争CYP2C19和CYP3A4的代谢，影响氯吡格雷的活性。<|>7)\n##\n(\"relationship\"<|>氯吡格雷<|>艾司奥美拉唑<|>艾司奥美拉唑能与氯吡格雷竞争CYP2C19和CYP3A4的代谢，影响氯吡格雷的活性。<|>7)\n##\n(\"relationship\"<|>氯吡格雷<|>兰索拉唑<|>兰索拉唑可作为与氯吡格雷合用的替代药物。<|>5)\n##\n(\"relationship\"<|>氯吡格雷<|>泮托拉唑<|>泮托拉唑可作为与氯吡格雷合用的替代药物。<|>5)\n##\n(\"relationship\"<|>氯吡格雷<|>雷贝拉唑<|>雷贝拉唑可作为与氯吡格雷合用的替代药物。<|>5)\n##\n(\"relationship\"<|>氯吡格雷<|>瑞格列奈<|>氯吡格雷的葡糖酸苷代谢物经CYP2C8代谢后显著抑制CYP2C8，能减慢瑞格列奈的代谢。<|>6)\n##\n(\"relationship\"<|>阿托伐他汀<|>环孢素<|>环孢素抑制CYP3A4、P-gp和OATP1B1，显著提高阿托伐他汀的血药浓度，增加肌病风险。<|>8)\n##\n(\"relationship\"<|>阿托伐他汀<|>吉非罗齐<|>吉非罗齐使阿托伐他汀的AUC增加，增加肌病风险。<|>7)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166503, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1598, "prompt_tokens": 2544, "total_tokens": 4142, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 752}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 华法林和R- 华法林的光学 异构体混合物。其中 S- 华法林的活性占 75% ，在体内 主要经过 CYP2C9 代谢，R- 华法林主要经过 CYP1A2 、 CYP3A4 、CYP2C19 代谢。 能够显著抑制 CYP2C9 活性 的药物均可能影响华法林的抗凝活性，导致出血或血栓 风险。另外，少数中成药或食物 / 果汁与华法林存在药 效学相互作用，增强或减弱其抗凝作用。华法林不宜与 抗骨质疏松药物、维生素 K2（ 四烯甲萘醌）合用。 一 般来说，华法林和其他药物合用没有绝对禁忌，通过检 测 INR，及时调整剂量可以实现安全合用的目的。\n4.5.2    阿司匹林  阿司匹林是常用的抗血小板药物，体 内不经CYP450 酶代谢，但是与甲氨蝶呤竞争肾脏有机 阴离子转运体，可能减慢甲氨蝶呤的排泄，增加其毒性。 布洛芬等NSAID 与阿司匹林竞争作用靶点—环氧合酶，\n\n\n\n·3538 · http://www.chinagp.net   E-mail:zgqkyx@chinagp.net.cn\n\n\n长期合用大剂量布洛芬等 NSAID 会严重削弱阿司匹林 的心血管保护作用，存在药效学相互作用。\n4.5.3    氯吡格雷  氯吡格雷是前体药物，本身没有活性， 在体内经过 CYP3A4 和 CYP2C19 代谢活化后，成为能 抑制血小板聚集的活性物质。奥美拉唑、艾司奥美拉唑\n\n\n　能和氯吡格雷竞争 CYP2C19 和 CYP3A4 的代谢， 导致 氯吡格雷活性过程受阻，影响其抗血小板活性。如果必 须合用质子泵抑制剂，可选择兰索拉唑、泮托拉唑和雷 贝拉唑。另外，氯吡格雷的葡糖酸苷代谢物经 CYP2C8  代谢后显著抑制 CYP2C8 ，因此能减慢瑞格列奈的代谢，\n\n表 3    血脂调节药相关药物相互作用的潜在危害及处置\nTable 3    Potential risk and management of drug interactions in lipid regulating medication\n药物名称\t联合药物\t临床后果\t药动学改变\t相互作用机制\t临床建议\n阿托伐他汀\t环孢素\t肌酸激酶升高、 肌病\t合用环孢素（5.2 mg ·kg-1   ·d-1 ）使阿托 伐 他 汀（10 mg/d）的 AUC 增 加 8.7 倍， Cmax 升高 10.7 倍。\t环 孢 素 抑 制 CYP3A4、P-gp 以 及 OATP1B1，显著提高阿托伐他汀的 AUC，升高血药浓度，增加肌病风险\t避免合用\n阿托伐他汀\t吉非罗齐\t肌酸激酶升高、 肌病\t　吉非罗齐使阿托伐他汀、2- 和 4- 羟基阿 托伐他汀酸的 AUC 分别增加 35%、51% 和 82%，使阿托伐他汀的\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_56e3440af0f2445e4ba7ea505dd6c063ec8f83c836e401f2ab33bef74c76531f_v2"}